findmyKOL
Clinical trialNCT03294577UnknownPhase 3Interventional

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

SponsorBeyondSpring Pharmaceuticals Inc.Enrollment221Chemotherapy-induced Neutropenia
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary purpose of this study is to compare the percentage of patients with Duration of Severe Neutropenia (DSN) =0 in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus Docetaxel, doxorubicin, and cyclophosphamide (TAC) + combination plinabulin/pegfilgrastim Severe neutropenia is an absolute neutrophil count (ANC) \<0.5 × 10\^9/L. Docetaxel, doxorubicin, and cyclophosphamide (TAC) will be used as the chemotherapy in this study.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Douglas Blayney, M.D.

    Stanford University School of Medicine - Cancer Institute

    Study Chair
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • No. 1 Banshandong Road

    Hangzhou, Gongshu District, China

  • Cancer Center of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Cancer Center of Guangzhou Medical University Breast Oncology

    Guangzhou, Guangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, Harbin, China

  • Fourth Hospital of Hebei Medical University Breast Cancer Department

    Shijiazhuang, Hebei, China

  • China-Japan Union Hospital of Jilin University Tumor Department of Hematology

    Changchun, Jilin, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, Shenyang, China

Ukraine
  • Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department

    Dnipro, Ukraine

  • Prykarpatskiy Regional Oncological Center

    Ivano-Frankivsk, Ukraine

  • Regional Clinical Oncology Center

    Kharkiv, Ukraine

  • V.T. Zaycev Institute

    Kharkiv, Ukraine

  • Kirovograd Regional Oncological Center

    Kropyvnytskyi, Ukraine

  • Public Institution Kryvyi Rih Oncology Center

    Krutyi Bereh, Ukraine

  • Hemotherapy Department

    Kyiv, Ukraine

  • Kyiv City Clinical Oncological Center

    Kyiv, Ukraine

  • Lviv State Oncological Regional

    Lviv, Ukraine

  • Odessa Regional Clinical Hospital Thoracic Surgery Department Academician Zabolotnoho

    Odesa, Ukraine

  • Zakarpattia Regional Clinical Oncology Center

    Uzhhorod, Ukraine

  • Vinnytsya Regional Clinical Oncology Dispensary

    Vinnytsia, Ukraine

  • Zaporizhia Regional Clinical Oncology Dispensary

    Zaporizhzhya, Ukraine

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Docetaxel →Pegfilgrastim →Plinabulin
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
23 Oct 2019
Primary completion
25 Sept 2020
Completion
25 Sept 2025
Last update posted
15 Jan 2021
Registered enrollment
221
Registry id
NCT03294577
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.